Granules India Ltd (GRANULES) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management confirmed a planned INR 2,000 crore growth capex over 3-4 years for peptide, US, and oncology capacity expansion.
- The first launch from its high-value, first-to-file pipeline is not expected for another 2.5 to 3 years, subject to litigation.
- Five new products will be launched in the US in H2 FY27, including two complex controlled substances expected to be significant growth drivers.
Performance Overview
- Achieved a record quarterly revenue, surpassing INR 15,000 million for the first time, marking the eighth consecutive quarter of sequential revenue growth.
- Sustained strong performance despite a challenging operating environment with geopolitical pressures impacting input and logistics costs.
- The US FDA conducted a cGMP inspection at the Gagillapur facility, resulting in 11 observations, which management believes are addressable.
- Progressed a value-led strategy by filing three potential sole first-to-file ANDAs, signaling a shift towards more complex and high-barrier products.
- Strengthened the balance sheet significantly, moving to a net cash position of INR 8,280 million following the receipt of warrant proceeds.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.